List of Tavneos drug patents

Tavneos is owned by Chemocentryx.

Tavneos contains Avacopan.

Tavneos has a total of 3 drug patents out of which 0 drug patents have expired.

Tavneos was authorised for market use on 07 October, 2021.

Tavneos is available in capsule;oral dosage forms.

Tavneos can be used as an adjunctive treatment of adult patients with tavneos (avacopan) with severe active anca-associated vasculitis (gpa and mpa) in combination with standard therapy including glucocorticoids.

Drug patent challenges can be filed against Tavneos from 2025-10-07.

The generics of Tavneos are possible to be released after 29 May, 2041.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8906938 CHEMOCENTRYX C5aR antagonists
Dec, 2029

(6 years from now)

US8445515 CHEMOCENTRYX C5aR antagonists
Feb, 2031

(7 years from now)

US11603356 CHEMOCENTRYX Amorphous form of a complement component C5a receptor
May, 2041

(17 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Oct 7, 2028
New Chemical Entity Exclusivity (NCE) Oct 7, 2026

Drugs and Companies using AVACOPAN ingredient

NCE-1 date: 2025-10-07

Market Authorisation Date: 07 October, 2021

Treatment: An adjunctive treatment of adult patients with tavneos (avacopan) with severe active anca-associated vasculitis (gpa and mpa) in combination with standard therapy including glucocorticoids

Dosage: CAPSULE;ORAL

More Information on Dosage

TAVNEOS family patents

17

United States

5

European Union

4

Japan

3

Denmark

3

Hungary

3

Spain

3

Portugal

2

Poland

2

Canada

2

Slovenia

2

Brazil

2

Lithuania

2

China

2

RS

2

Croatia

1

Korea, Republic of

1

Ukraine

1

Hong Kong

1

Taiwan

1

Morocco

1

Netherlands

1

Argentina

1

Mexico

1

New Zealand

EA

1

EA

1

Colombia

1

Australia

1

Norway

1

South Africa

1

Singapore

1

Israel

1

Jordan

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in